Today's Stocks Driving Success For The Drugs Industry

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 18 points (0.1%) at 15,482 as of Monday, July 15, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,893 issues advancing vs. 1,042 declining with 108 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.1%. A company within the industry that fell today was Novo Nordisk A/S ( NVO), up 0.7%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Idexx Laboratories ( IDXX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Idexx Laboratories is up $2.48 (2.6%) to $96.37 on heavy volume. Thus far, 406,641 shares of Idexx Laboratories exchanged hands as compared to its average daily volume of 526,300 shares. The stock has ranged in price between $95.60-$96.97 after having opened the day at $95.60 as compared to the previous trading day's close of $93.89.

IDEXX Laboratories, Inc. develops, manufactures, and distributes various products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. Idexx Laboratories has a market cap of $5.0 billion and is part of the health care sector. Shares are up 0.5% year to date as of the close of trading on Friday. Currently there are 3 analysts that rate Idexx Laboratories a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Idexx Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Idexx Laboratories Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, MannKind Corporation ( MNKD) is up $0.46 (6.6%) to $7.42 on average volume. Thus far, 5.4 million shares of MannKind Corporation exchanged hands as compared to its average daily volume of 8.0 million shares. The stock has ranged in price between $6.96-$7.48 after having opened the day at $7.03 as compared to the previous trading day's close of $6.96.

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. MannKind Corporation has a market cap of $2.0 billion and is part of the health care sector. Shares are up 200.0% year to date as of the close of trading on Friday. Currently there are 3 analysts that rate MannKind Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates MannKind Corporation as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins and weak operating cash flow. Get the full MannKind Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Illumina ( ILMN) is up $1.13 (1.5%) to $76.03 on average volume. Thus far, 630,604 shares of Illumina exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $74.50-$76.45 after having opened the day at $74.50 as compared to the previous trading day's close of $74.90.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $9.5 billion and is part of the health care sector. Shares are up 36.7% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Illumina Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Herbalife ( HLF) is up $3.09 (6.3%) to $52.12 on average volume. Thus far, 1.5 million shares of Herbalife exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $49.30-$52.35 after having opened the day at $49.30 as compared to the previous trading day's close of $49.03.

Herbalife Ltd., a network marketing company, sells weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products worldwide. Herbalife has a market cap of $5.1 billion and is part of the consumer goods sector. Shares are up 50.6% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Herbalife a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Herbalife as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Herbalife Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Allergan ( AGN) is up $0.82 (0.9%) to $91.33 on light volume. Thus far, 648,115 shares of Allergan exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $90.06-$91.48 after having opened the day at $91.44 as compared to the previous trading day's close of $90.51.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $26.5 billion and is part of the health care sector. Shares are down 2.5% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Allergan a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

General Mills Buys Blue Buffalo for $8 Billion -- Who's Next?

General Mills Buys Blue Buffalo for $8 Billion -- Who's Next?

Cramer: These Stocks Are on a Mission Right Now

Cramer: These Stocks Are on a Mission Right Now

Don't Fall for the Downward Bias: Cramer's 'Mad Money' Recap (Thursday, 2/1/18)

Don't Fall for the Downward Bias: Cramer's 'Mad Money' Recap (Thursday, 2/1/18)

Cramer: What Stocks Are On a Mission Right Now?

Cramer: What Stocks Are On a Mission Right Now?

Meet TheStreet's Pets! They May Be Expensive -- But We Love Them!

Meet TheStreet's Pets! They May Be Expensive -- But We Love Them!